SECsense Logo

Emergent BioSolutions Inc. 8-K Filing Insights: Key Updates from January 14, 2025

$EBS
Form 8-K
Filed on: 2025-01-14
Source
Emergent BioSolutions Inc. 8-K Filing Insights: Key Updates from January 14, 2025

Here are the key insights extracted from the provided section of the financial report:

  1. Entity Information:
  • Company Name: Emergent BioSolutions Inc.
  • CIK (Central Index Key): 0001367644
  • Industry: Biotechnology (implied from the company name).
  • Address: 300 Professional Drive, Gaithersburg, MD 20879.
  • Contact Number: 240-631-3200.
  1. SEC Filing Details:
  • Filing Type: 8-K (a report of unscheduled material events or corporate changes).
  • Filing Date: January 14, 2025.
  • Period Covered: The report covers the same date (January 14, 2025).
  1. Stock Information:
  • Common Stock: The company has common stock with a par value of $0.001 per share.
  • Stock Symbol: EBS.
  • Exchange: NYSE (New York Stock Exchange).
  1. Document Schema:
  • The filing references an XML schema (ebs-20250114.xsd), which is standard for XBRL filings.

Insights:

  • The filing is an 8-K, which typically indicates a significant event or change within the company. Investors should look for specific disclosures associated with this filing date for any material impact on the company's operations or financials.
  • The company is publicly traded on the NYSE under the ticker symbol EBS, which indicates it is subject to public reporting requirements and regulatory scrutiny.
  • The presence of a specific schema suggests that the report may contain structured financial data, which can be useful for analysis.

Overall, this filing marks a significant date for Emergent BioSolutions Inc., and stakeholders should analyze the contents of the 8-K for further insights into the company's current status or any recent developments.